TG Therapeutics TGTX License — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's license — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's license — revenue?
- TG Therapeutics (TGTX) reported license — revenue of $3.61M in Q1 2026.
- How has TG Therapeutics's license — revenue changed year-over-year?
- TG Therapeutics's license — revenue increased by 200.6% year-over-year, from $1.2M to $3.61M.
- What is the long-term trend for TG Therapeutics's license — revenue?
- Over 4 years (2021 to 2025), TG Therapeutics's license — revenue has grown at a 180.1% compound annual growth rate (CAGR), from $152K to $9.36M.
- What does license — revenue mean?
- Revenue earned by granting other companies the rights to use the company's intellectual property or pharmaceutical assets.
- How do you interpret license — revenue?
- An increase suggests successful monetization of the R&D pipeline or new partnership agreements, while a decrease may indicate the expiration of existing licenses or a shift in business strategy away from out-licensing.
- How does license — revenue compare across companies?
- Biotechnology peers often report this as 'License and Collaboration Revenue,' which is typically characterized by lumpy, non-linear cash flows depending on milestone achievement.